Poornima Sharma

Vardhman Mahavir Medical College & Safdarjung Hospital

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma”.

FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3803

N/A

2.6DataRank · unranked

94 citations

Bindu Kanapuru, Bindu George, Xue Lin, Zhenzhen Xu, Wilson W. Bryan +3 more

Effect of COVID-19 Pandemic on Knowledge, Attitude and Practices Towards Antenatal Care Among Antenatal Women: A Study From a Tertiary Care Hospital in Delhi, India

Cureus(2024)10.7759/cureus.52618

N/A

0.165DataRank · unranked

2 citations

Poornima Sharma, Shiwani Tripathi, Divya Arora, Ambika Agarwal, Abhigya Malik +3 more

FDA Approval Summary: Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0568

N/A

0DataRank · unranked

24 citations

Yvette L. Kasamon, Xue Lin, Zhenzhen Xu, Marc R. Theoret, Tejashri Purohit-Sheth +1 more

FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class–Exposed, Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-4181

N/A

0DataRank · unranked

8 citations

Xue Lin, Zhenzhen Xu, Bindu Kanapuru, Marc R. Theoret, Robert Sokolic +2 more